Oragenics Inc.(OGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OGEN Oragenics Inc.

盘后交易 06-29 17:54:06 EDT

0.5900

+0.0029

+0.49%

盘后0.5900

+0.00000.00%

16:10 EDT

最高0.5900	最低0.5751	成交量4.48万
今开0.5900	昨收0.5871	日振幅2.54%
总市值266.21万	流通市值249.96万	总股本451.20万
成交额2.62万	换手率1.06%	流通股本423.66万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OGEN","market":"US","secType":"STK","nameCN":"Oragenics Inc.","latestPrice":0.59,"timestamp":1782763200000,"preClose":0.5871,"halted":0,"volume":44780,"hourTrading":{"tag":"盘后","latestPrice":0.59,"preClose":0.59,"latestTime":"16:10 EDT","volume":3,"amount":1.77,"timestamp":1782763804970,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00493953329926761,"floatShares":4236600,"shares":4512000,"eps":-6.1211,"marketStatus":"盘后交易","change":0.0029,"latestTime":"06-29 17:54:06 EDT","open":0.59,"high":0.59,"low":0.5751,"amount":26221,"amplitude":0.025379,"askPrice":0.6475,"askSize":100,"bidPrice":0.5236,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.1211,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782777600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.5871,"preHourTrading":{"tag":"盘前","latestPrice":0.5991,"preClose":0.57,"latestTime":"08:47 EDT","volume":3741,"amount":2231.34586146,"timestamp":1782737246471,"change":0.0291,"changeRate":0.051053,"amplitude":0.022632},"postHourTrading":{"tag":"盘后","latestPrice":0.59,"preClose":0.59,"latestTime":"16:10 EDT","volume":3,"amount":1.77,"timestamp":1782763804970,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.144256},"requestUrl":"/m/hq/s/OGEN","defaultTab":"news","newsList":[{"id":"1179783235","title":"Oragenics Inc. 将在获得FDA批准后为授权技术销售收入支付六年3%的特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1179783235","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179783235?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:32","pubTimestamp":1778157137,"startTime":"0","endTime":"0","summary":"Oragenics Inc. 已达成一项关键商业协议，规定该公司在获得美国食品药品监督管理局（FDA）对其授权技术产品的批准后，将在随后六年内按相关销售收入支付3%的特许权使用费。\n这一安排明确了该公司的财务义务，同时为其技术商业化提供了清晰的收入分配框架。协议期限设定为六年，为双方合作提供了稳定的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGEN","SIGY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123268050","title":"Oragenics签署意向书 获Sigyn Therapeutics授权Cardiodialysis™技术用于靶向TBI诱发的全身性炎症","url":"https://stock-news.laohu8.com/highlight/detail?id=1123268050","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123268050?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:31","pubTimestamp":1778157088,"startTime":"0","endTime":"0","summary":"Oragenics Inc.  已与Sigyn Therapeutics Inc.  达成技术授权意向协议，将引进后者的Cardiodialysis血液净化技术平台。该合作旨在开发针对创伤性脑损伤引发的全身性炎症的创新疗法。根据协议条款，Oragenics计划通过Cardiodialysis技术清除患者血液中由脑损伤触发的炎性介质。此次合作标志着Oragenics在神经疾病治疗领域的战略延伸。公司将结合其在血脑屏障穿透技术方面的积累，与Sigyn Therapeutics的血液净化专长形成协同效应。双方预计在完成技术验证后推进临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SIGY","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109053111","title":"Oragenics Inc获独家授权 开发心脑透析技术治疗脑损伤与神经退行性疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1109053111","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109053111?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:19","pubTimestamp":1778156356,"startTime":"0","endTime":"0","summary":"生物技术公司Oragenics Inc.（纳斯达克代码：OGEN）近日向美国证券交易委员会提交文件，宣布将获得一项针对创伤性脑损伤及神经退行性疾病的心脑透析技术独家授权许可。\n该技术旨在通过创新疗法应对中枢神经系统疾病领域的医疗需求。此次独家授权标志着Oragenics在神经科学治疗领域的战略布局取得重要进展。\n根据披露文件，心脑透析技术有望为创伤性脑损伤和阿尔茨海默症等神经退行性疾病患者提供新的治疗选择。该公司未在文件中透露授权协议的具体条款及后续研发计划时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131122330","title":"Oragenics Inc. 签署意向书 拟从Sigyn Therapeutics获得心肾透析技术授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1131122330","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131122330?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:19","pubTimestamp":1778156355,"startTime":"0","endTime":"0","summary":"Oragenics Inc. 近日宣布与Sigyn Therapeutics达成协议，签署关于心肾透析（Cardiodialysis）技术的授权意向书。根据美国证券交易委员会（SEC）公开文件显示，该意向书的签署标志着两家公司在医疗技术领域的合作取得重要进展。\n心肾透析技术作为新型治疗手段，旨在为心肾综合征患者提供创新解决方案。此次授权合作若最终落地，将有望拓宽Oragenics Inc. 的产品管线，增强其在生物医药领域的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157144643","title":"Oragenics启动ONP-002治疗脑震荡和轻度创伤性脑损伤IIa期临床试验第二中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1157144643","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157144643?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:49","pubTimestamp":1777985393,"startTime":"0","endTime":"0","summary":"生物制药公司Oragenics宣布，其针对脑震荡和轻度创伤性脑损伤的创新疗法ONP-002已启动IIa期临床试验的第二个研究中心。这一进展标志着该药物临床开发计划的重要里程碑。\n根据公司规划，IIa期临床数据的初步结果预计将在2026年底前公布。这些关键数据将为计划向美国食品药品监督管理局提交的研究性新药申请提供支持。\n公司同时制定了明确的后续开发时间表，目标在12月31日前启动针对美国市场的IIb期临床试验。这一系列举措彰显了Oragenics在神经科学治疗领域加速推进药物研发的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111822434","title":"Oragenics启动Onp-002治疗脑震荡及轻度创伤性脑损伤IIa期临床试验第二研究中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1111822434","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111822434?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:33","pubTimestamp":1777984395,"startTime":"0","endTime":"0","summary":"Oragenics公司已正式启动其创新药物Onp-002针对脑震荡与轻度创伤性脑损伤治疗的IIa期临床试验第二处研究中心。该重要进展标志着该项目在多中心临床研究部署上取得实质性突破，为加速患者入组与数据收集工作奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181066695","title":"Oragenics公布ONP-002治疗轻度创伤性脑损伤IIa期临床试验完成8次研究药物剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1181066695","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181066695?lang=zh_cn&edition=full","pubTime":"2026-04-20 21:02","pubTimestamp":1776690154,"startTime":"0","endTime":"0","summary":"生物制药公司Oragenics Inc.（简称Oragenics）近日宣布，其针对轻度创伤性脑损伤（mTBI）的候选药物ONP-002，在IIa期临床试验中已完成8次研究药物的给药。这一进展标志着该药物在临床开发阶段取得了重要步骤，为后续疗效和安全性评估奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192449171","title":"Oragenics探索拓展中枢神经系统平台，拟收购脑健康、神经修复与神经保护领域资产","url":"https://stock-news.laohu8.com/highlight/detail?id=1192449171","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192449171?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:33","pubTimestamp":1773232399,"startTime":"0","endTime":"0","summary":"Oragenics公司正积极探索其中枢神经系统（CNS）平台的扩展计划，旨在通过收购脑健康、神经修复及神经保护领域的相关资产，加强其在该领域的布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136071513","title":"Oragenics获澳大利亚HREC批准启动ONP-002治疗脑震荡及轻度创伤性脑损伤的IIa期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136071513","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136071513?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:32","pubTimestamp":1773145940,"startTime":"0","endTime":"0","summary":"生物制药公司Oragenics Inc.近日宣布，其创新药物ONP-002已获得澳大利亚人类研究伦理委员会的正式批准，将开展针对脑震荡和轻度创伤性脑损伤治疗的IIa期临床试验。脑震荡与轻度创伤性脑损伤是常见的神经系统疾病，尤其在运动损伤和交通事故中高发。Oragenics首席执行官表示，公司正加速推进临床试验的准备工作，计划在近期完成首例患者入组。此次获批不仅验证了ONP-002的研发价值，也为后续全球多中心临床研究奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616896105","title":"Oragenics Inc.盘中异动 早盘快速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616896105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616896105?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:47","pubTimestamp":1772549271,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时47分，Oragenics Inc.股票出现波动，股价大幅下跌5.00%。截至发稿，该股报0.790美元/股，成交量2487股，换手率0.06%，振幅0.00%。Oragenics Inc.股票所在的生物技术行业中，整体跌幅为1.32%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303224751a69e0ce9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303224751a69e0ce9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178350932","title":"Oragenics携手Duck Flats Pharma，推进脑震荡项目FDA新药临床申请准备及临床试验设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1178350932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178350932?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:30","pubTimestamp":1770125420,"startTime":"0","endTime":"0","summary":"生物制药公司Oragenics Inc. (NYSE American: OGEN) 已宣布与Duck Flats Pharma达成战略合作，旨在共同支持其脑震荡治疗项目的新药临床申请准备工作以及后续临床试验方案的设计。这一合作将整合双方在神经科学领域的专业知识和资源，加速该治疗方案的开发进程，以满足美国食品药品监督管理局的监管要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592143151","title":"Oragenics Inc.盘中异动 快速上涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592143151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592143151?lang=zh_cn&edition=full","pubTime":"2025-12-20 00:13","pubTimestamp":1766160781,"startTime":"0","endTime":"0","summary":"北京时间2025年12月20日00时13分，Oragenics Inc.股票出现波动，股价急速上涨5.14%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为1.42%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Novabay Pharmaceuticals, Inc.、爱美医疗涨幅较大，Psyence Biomedical Ltd.、In8Bio, Inc.、Neuraxis, Inc.较为活跃，换手率分别为1607.84%、214.16%、127.99%，振幅较大的相关个股有Geovax Labs, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Gain Therapeutics, Inc.，振幅分别为57.35%、46.49%、38.67%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220001301a6b7dc8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220001301a6b7dc8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585239951","title":"Oragenics Inc.盘中异动 早盘股价大跌10.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585239951","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585239951?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:52","pubTimestamp":1763736767,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日22时52分，Oragenics Inc.股票出现波动，股价快速下跌10.18%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Osr Holdings, Inc.、Dermata Therapeutics Inc C/Wts 、木薯科学涨幅较大，Osr Holdings, Inc.、Psyence Biomedical Ltd.、Telomir Pharmaceuticals, Inc.较为活跃，换手率分别为141.44%、14.20%、14.05%，振幅较大的相关个股有Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Sangamo Therapeutics, Inc.、Osr Holdings, Inc.，振幅分别为38.69%、36.42%、28.82%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121225247a4b1e463&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121225247a4b1e463&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227863","title":"Oragenics Inc.盘中异动 快速拉升5.60%报0.300美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227863","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518227863?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:42","pubTimestamp":1741614167,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时42分，Oragenics Inc.股票出现异动，股价急速上涨5.60%。截至发稿，该股报0.300美元/股，成交量16.2141万股，换手率1.18%，振幅7.57%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2320.78%、538.31%、80.67%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为38.70%、28.59%、25.35%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214247964038f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214247964038f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514438567","title":"Oragenics Inc.盘中异动 股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514438567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514438567?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:33","pubTimestamp":1740666783,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时33分，Oragenics Inc.股票出现异动，股价快速下跌5.07%。截至发稿，该股报0.266美元/股，成交量5.5419万股，换手率0.40%，振幅0.00%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223303abdf6f0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223303abdf6f0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513720617","title":"Oragenics Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720617","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513720617?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:01","pubTimestamp":1740409287,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时01分，Oragenics Inc.股票出现波动，股价急速下挫5.08%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为154.64%、68.82%、25.12%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242301279890fd34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242301279890fd34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510569380","title":"Oragenics Inc.盘中异动 股价大涨5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510569380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510569380?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:46","pubTimestamp":1739285208,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时46分，Oragenics Inc.股票出现异动，股价急速拉升5.36%。Oragenics Inc.股票所在的生物技术行业中，整体跌幅为1.60%。其相关个股中，Dominari Holdings Inc.、Ocean Biomedical, Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2346.65%、630.97%、267.20%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为40.26%、33.04%、33.02%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112246489881bff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112246489881bff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509427298","title":"Oragenics Inc.盘中异动 急速下跌6.93%报0.276美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509427298","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509427298?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:31","pubTimestamp":1738852289,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时31分，Oragenics Inc.股票出现波动，股价大幅跳水6.93%。截至发稿，该股报0.276美元/股，成交量232.456万股，换手率16.96%，振幅2.47%。Oragenics Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223129a23bce1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223129a23bce1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509601282","title":"Oragenics Inc.盘中异动 股价大涨88.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509601282","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509601282?lang=zh_cn&edition=full","pubTime":"2025-02-05 22:30","pubTimestamp":1738765804,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日22时30分，Oragenics Inc.股票出现波动，股价大幅拉升88.00%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Oragenics Inc.、Nanoviricides, Inc.、Cognition Therapeutics, Inc.涨幅较大，Pasithea Therapeutics Corp.、60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.较为活跃，换手率分别为1970.72%、561.06%、552.84%，振幅较大的相关个股有Kairos Pharma, Ltd.、Can Fite Biopharma Ltd、Actinium Pharmaceuticals, Inc. ，振幅分别为5.75%、4.32%、2.56%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223005987b7b61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223005987b7b61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508463821","title":"Oragenics Inc.股价重挫10.62% 市值跌1.79万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508463821","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508463821?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:09","pubTimestamp":1738681755,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时09分，Oragenics Inc.股票出现异动，股价急速下跌10.62%。截至发稿，该股报0.260美元/股，成交量6.3472万股，换手率0.46%，振幅4.92%。Oragenics Inc.股票所在的生物技术行业中，整体涨幅为1.03%。Oragenics Inc.公司简介：Oragenics Inc从事神经病学和抗感染性疾病领域鼻腔给药药物的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204230915a2393099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204230915a2393099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OGEN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oragenics.com;ir.oragenics.com","stockEarnings":[{"period":"1week","weight":0.0686},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.1077},{"period":"6month","weight":-0.3165},{"period":"1year","weight":-0.8318},{"period":"ytd","weight":-0.2504}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Oragenics, Inc.（前身为oragen股份有限公司）成立于1996年11月，但是经营活动直到1999年才开始。该公司是一家处于发展阶段的公司，致力于神经内科和抗击传染病领域鼻腔给药药物的研发。公司主导产品ONP-002是一种全合成、非天然存在的神经类固醇，具有亲脂性，可穿越血脑屏障，快速减轻肿胀、氧化应激和炎症，同时通过基因扩增恢复适当的血流。","yearOnYearQuotes":[{"month":1,"riseRate":0.470588,"avgChangeRate":0.013573},{"month":2,"riseRate":0.352941,"avgChangeRate":0.02296},{"month":3,"riseRate":0.176471,"avgChangeRate":-0.161308},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.08901},{"month":5,"riseRate":0.5,"avgChangeRate":0.015673},{"month":6,"riseRate":0.526316,"avgChangeRate":0.018623},{"month":7,"riseRate":0.5,"avgChangeRate":0.048595},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.089281},{"month":9,"riseRate":0.333333,"avgChangeRate":0.021879},{"month":10,"riseRate":0.277778,"avgChangeRate":-0.062073},{"month":11,"riseRate":0.5,"avgChangeRate":0.075378},{"month":12,"riseRate":0.222222,"avgChangeRate":-0.117074}],"exchange":"AMEX","name":"Oragenics Inc.","nameEN":"Oragenics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oragenics Inc.(OGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Oragenics Inc.(OGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Oragenics Inc.,OGEN,Oragenics Inc.股票,Oragenics Inc.股票老虎,Oragenics Inc.股票老虎国际,Oragenics Inc.行情,Oragenics Inc.股票行情,Oragenics Inc.股价,Oragenics Inc.股市,Oragenics Inc.股票价格,Oragenics Inc.股票交易,Oragenics Inc.股票购买,Oragenics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oragenics Inc.(OGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Oragenics Inc.(OGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}